Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 47Breast Neoplasms 46Colorectal Neoplasms 28Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Glioblastoma 19Pancreatic Neoplasms 17Melanoma 17Lung Neoplasms 17Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Rectal Neoplasms 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Sarcoma 6Leukemia 6

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Advance Solid Tumors × Clear all
NCT07529535 2026-04-17

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Zhejiang Anglikang Pharmaceutical Co., Ltd.

Phase 1 Suspended
16 enrolled
Other solid neoplasm

Advance Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡